Richard Muruve - Arch Biopartners President CEO, Director
| ARCH Stock | CAD 1.95 0.01 0.51% |
CEO
Mr. Richard Muruve is President, Chief Executive Officer, Director of Arch Biopartners Inc. Prior to his involvement with the Corporationrationration, Mr. Muruve spent 12 years working at the Bank of Montreal in the Investment Banking Group. He has a MBA degree from the University of British Columbia and a Bachelor of Commerce from McGill University. since 2010.
| Age | 53 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Address | 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5 |
| Phone | 647 428 7031 |
| Web | https://www.archbiopartners.com |
Arch Biopartners Management Efficiency
The company has return on total asset (ROA) of (0.812) % which means that it has lost $0.812 on every $100 spent on assets. This is way below average. Arch Biopartners' management efficiency ratios could be used to measure how well Arch Biopartners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 14.13 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (2.8 K). At this time, Arch Biopartners' Total Current Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.32 in 2024, whereas Other Current Assets are likely to drop slightly above 39.8 K in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Michael Kelly | NervGen Pharma Corp | 58 | |
| Adrian Mendes | Perimeter Medical Imaging | N/A | |
Management Performance
| Return On Asset | -0.81 |
Arch Biopartners Leadership Team
Elected by the shareholders, the Arch Biopartners' board of directors comprises two types of representatives: Arch Biopartners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Biopartners' management team and ensure that shareholders' interests are well served. Arch Biopartners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Biopartners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel MD, Chief CoFounder | ||
| Andrew CFA, Acting Director | ||
| Daniel Muruve, Chief Science Officer | ||
| Paul Beck, CoFounder Scientist | ||
| Aaron Benson, Director Communications | ||
| Richard Muruve, President CEO, Director | ||
| Justin MacDonald, CoFounder Scientist |
Arch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arch Biopartners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.81 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | 132.23 M | ||||
| Shares Outstanding | 64.94 M | ||||
| Shares Owned By Insiders | 19.86 % | ||||
| Number Of Shares Shorted | 3.97 K | ||||
| Price To Sales | 91.52 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | (502.88 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.